Specifically, our variant annotation and classification process did not evaluate many rare missense variants, particularly those in PALB2, ATM, and CHEK2. We also did not evaluate variants in additional genes, such as BARD1, CDH1, PTEN, RAD51C, RAD51D, STK11, or TP53, which could increase the risk of breast cancer. This evidence concerns the gene PALB2 and breast cancer.